Literature DB >> 12531896

The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase.

Olivier Pluquet1, Sophie North, Anindita Bhoumik, Konstantinos Dimas, Ze'ev Ronai, Pierre Hainaut.   

Abstract

WR1065 is an aminothiol with selective cytoprotective effects in normal cells compared with cancer cells. In a previous study (North, S., El-Ghissassi, F., Pluquet, O., Verhaegh, G., and Hainaut, P. (2000) Oncogene 19, 1206-1214), we have shown that WR1065 activates wild-type p53 in cultured cells. Here we show that WR1065 induces p53 to accumulate through escape from proteasome-dependent degradation. This accumulation is not prevented by inhibitors of phosphatidylinositol 3-kinases and is not accompanied by phosphorylation of Ser-15, -20, or -37, which are common targets of the kinases activated in response to DNA damage. Furthermore, WR1065 activates the JNK (c-Jun N-terminal kinase), decreases complex formation between p53 and inactive JNK, and phosphorylates p53 at Thr-81, a known site of phosphorylation by JNK. A dominant negative form of JNK (JNK-APF) reduces by 50% the activation of p53 by WR1065. Thus, WR1065 activates p53 through a JNK-dependent signaling pathway. This pathway may prove useful for pharmacological modulation of p53 activity through non-genotoxic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531896     DOI: 10.1074/jbc.M207396200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  The radioprotective agent WR1065 protects cells from radiation damage by regulating the activity of the Tip60 acetyltransferase.

Authors:  Ye Xu; Kalindi Parmar; Fengxia Du; Brendan D Price; Yingli Sun
Journal:  Int J Biochem Mol Biol       Date:  2011-10-20

2.  Ultraviolet irradiation-induced K(+) channel activity involving p53 activation in corneal epithelial cells.

Authors:  Ling Wang; Wei Dai; Luo Lu
Journal:  Oncogene       Date:  2005-04-21       Impact factor: 9.867

Review 3.  Stress-induced corneal epithelial apoptosis mediated by K+ channel activation.

Authors:  Luo Lu
Journal:  Prog Retin Eye Res       Date:  2006-09-07       Impact factor: 21.198

Review 4.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

5.  The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

Authors:  S Dedieu; X Canron; H R Rezvani; M Bouchecareilh; F Mazurier; R Sinisi; M Zanda; M Moenner; A Bikfalvi; S North
Journal:  BMC Med       Date:  2010-03-24       Impact factor: 8.775

6.  Amifostine alleviates radiation-induced lethal small bowel damage via promotion of 14-3-3σ-mediated nuclear p53 accumulation.

Authors:  Eng-Yen Huang; Feng-Sheng Wang; Yu-Min Chen; Yi-Fan Chen; Chung-Chi Wang; I-Hui Lin; Yu-Jie Huang; Kuender D Yang
Journal:  Oncotarget       Date:  2014-10-30

Review 7.  Comments on the mechanisms of action of radiation protective agents: basis components and their polyvalence.

Authors:  Mikhail V Vasin
Journal:  Springerplus       Date:  2014-08-07

8.  Role of p53 and transcription-independent p53-induced apoptosis in shear-stimulated megakaryocytic maturation, particle generation, and platelet biogenesis.

Authors:  Stephanie A Luff; Chen-Yuan Kao; Eleftherios T Papoutsakis
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

9.  Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.

Authors:  Miriam C Poirier; Ofelia A Olivero; Andrew W Hardy; Genoveffa Franchini; Jennifer P Borojerdi; Vernon E Walker; Dale M Walker; Gene M Shearer
Journal:  AIDS Res Ther       Date:  2009-11-06       Impact factor: 2.250

Review 10.  Targeting Oncogenic Mutant p53 for Cancer Therapy.

Authors:  Alejandro Parrales; Tomoo Iwakuma
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.